Published in Intervirology on January 01, 2005
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis (2009) 1.15
Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2010) 0.97
Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.91
Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One (2014) 0.90
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget (2015) 0.90
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol (2007) 0.87
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol (2013) 0.83
A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol (2013) 0.83
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol (2007) 0.82
Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One (2013) 0.80
Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol (2016) 0.79
Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int (2010) 0.78
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol (2015) 0.78
Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep (2015) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Incidence and management of bile leakage after hepatic resection for malignant hepatic tumors. J Am Coll Surg (2002) 2.00
Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA (2004) 1.78
Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol (2005) 1.72
Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res (2005) 1.64
Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci (2004) 1.48
Risk factor analysis in patients with liver cirrhosis undergoing cardiovascular operations. Ann Thorac Surg (2010) 1.48
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol (2002) 1.42
Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci (2003) 1.36
Impact of laparoscopic liver resection for hepatocellular carcinoma with F4-liver cirrhosis. Surg Endosc (2013) 1.27
Outcomes of hepatic resection for hepatolithiasis. Am J Surg (2009) 1.26
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res (2015) 1.23
Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res (2007) 1.13
Laparoscopic excision of a retroperitoneal cystic lymphangioma: report of a case. Surg Today (2003) 1.13
Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2007) 1.12
Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res (2003) 1.11
Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'? J Gastroenterol (2013) 1.08
Surgical management of cystic hepatic neoplasms. J Gastroenterol (2003) 1.08
Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: Immunohistochemical evidence. Hepatol Res (2005) 1.07
Eosinophilic enteritis presenting as acute intestinal obstruction: a case report and review of the literature. Dig Surg (2003) 1.05
Asymptomatic thrombosis as a late complication of a retrohepatic vena caval graft performed for primary leiomyosarcoma of the inferior vena cava: report of a case. Surg Today (2002) 1.04
Risk factors for postoperative delirium after liver resection for hepatocellular carcinoma. World J Surg (2004) 1.04
Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol (2010) 1.00
Predictive factors for surgical indication in adhesive small bowel obstruction. Am J Surg (2008) 0.99
Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg (2005) 0.99
Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2011) 0.98
Asymptomatic chronic intestinal ischemia caused by idiopathic phlebosclerosis of mesenteric vein. Dig Dis Sci (2002) 0.97
p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection. Intervirology (2004) 0.97
CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology (2004) 0.95
Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res (2010) 0.95
Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol (2009) 0.94
Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg (2008) 0.94
Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res (2006) 0.94
Self-expanding metallic stent for benign biliary strictures: seven-year follow-up. Hepatogastroenterology (2004) 0.94
Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol (2008) 0.94
Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab (2006) 0.94
Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol (2011) 0.94
The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer (2013) 0.94
Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl (2013) 0.94
Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2014) 0.93
Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res (2003) 0.93
Nutritional risk index as an independent predictive factor for the development of surgical site infection after pancreaticoduodenectomy. Surg Today (2012) 0.93
Surgical strategy for hepatocellular carcinoma originating in the caudate lobe. Surgery (2004) 0.93
Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet (2004) 0.92
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol (2007) 0.92
Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med (2008) 0.91
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. J Hepatol (2011) 0.91
Pseudotumor of the omentum with a fishbone nucleus. J Gastroenterol Hepatol (2007) 0.91
Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol (2009) 0.90
A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg (2008) 0.90
Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci (2012) 0.90
Percutaneous transhepatic metallic stent placement for malignant portal vein stenosis. Hepatogastroenterology (2003) 0.90
Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol (2013) 0.90
Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res (2010) 0.90
Intracystic hemorrhage with spontaneous rupture of liver cyst complicated by infection: a case report. Osaka City Med J (2003) 0.89
Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med (2006) 0.89
HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol (2003) 0.89
Successful treatment of giant rectal varices by modified percutaneous transhepatic obliteration with sclerosant: Report of a case. World J Gastroenterol (2006) 0.89
Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res (2013) 0.88
Secondary hemocholecyst after radiofrequency ablation therapy for hepatocellular carcinoma. J Gastroenterol (2003) 0.88
Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J Med Virol (2005) 0.88
Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg (2005) 0.88
Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg (2013) 0.88
Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. Hepatol Res (2011) 0.86
A long-term survivor of intrahepatic cholangiocarcinoma with paraaortic lymph node metastasis. J Gastroenterol (2006) 0.86
S-allyl cysteine prevents CCl(4)-induced acute liver injury in rats. Free Radic Res (2007) 0.85
Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. Hepatol Res (2012) 0.85
Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology (2002) 0.84
A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl (2009) 0.84
Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol (2003) 0.84
Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med (2007) 0.84
Adenomyoma of the common hepatic duct mimicking bile duct cancer: report of a case. Surg Today (2007) 0.84
Surgical repair of a liver injury in a patient: accompanied with tricuspid regurgitation. Hepatogastroenterology (2003) 0.84
Clinicopathologic characteristics of hepatitis C virus-associated intrahepatic cholangiocarcinoma. Dig Surg (2006) 0.84
Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol (2005) 0.84
Multicentric occurrence of hepatocellular carcinoma in patients with a somatic mutation of mitochondorial DNA and hepatitis C virus. Hepatol Res (2003) 0.84
Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today (2006) 0.84
A case of primary small cell carcinoma of the liver that was treated with chemotherapy. Hepatol Int (2008) 0.84
Hepatectomy with transcatheter arterial embolization for large hepatoma in the caudate lobe. Hepatogastroenterology (2003) 0.83
Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol (2004) 0.83
Surgery for segmental primary sclerosing cholangitis. Hepatogastroenterology (2004) 0.83
Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases. J Gastroenterol (2003) 0.83
Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res (2002) 0.82
Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. J Hepatobiliary Pancreat Sci (2009) 0.82
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma. Intern Med (2013) 0.82
The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol (2011) 0.82
Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res (2014) 0.82
Correlation between dynamic computed tomographic and histopathological findings in the diagnosis of small hepatocellular carcinoma. Dig Surg (2004) 0.82
Portal vein thrombosis following percutaneous ethanol injection therapy for hepatocellular carcinoma. Indian J Gastroenterol (2002) 0.82
The separate-lesion type combined hepatocellular carcinoma and cholangiocarcinoma. Hepatogastroenterology (2002) 0.82
Limy bile: a case of obstructive jaundice and review of 26 cases. Osaka City Med J (2003) 0.82
Features and outcome after liver resection for non-B non-C hepatocellular carcinoma. Hepatogastroenterology (2012) 0.82
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol (2011) 0.81
Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol (2008) 0.81
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. J Gastroenterol (2011) 0.81